BLGO Pengajuan SEC - BioLargo, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

880242

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioLargo, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 15, 2025	EX-99.1	EXHIBIT 99.1 Exhibit 99.1
August 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Num
August 14, 2025	EX-10.20	First amendment to Preferred Master Manufacturing Agreement between ONM Environmental, Inc., and Ikigai Holdings, LLC, dated June 6, 2025 Exhibit 10.20 FIRST AMENDMENT TO PREFERRED MASTER MANUFACTURING AGREEMENT This FIRST AMENDMENT TO PREFERRED MASTER MANUFACTURING AGREEMENT (this “Amendment”) is made as of June 6, 2025 (“Amendment Date”) by and between ONM Environmental, Inc., a California corporation (“Seller”), and Ikigai Holdings, LLC, a Nevada limited liability company and Pooph Inc., a Nevada corporation (collectively, “Buyer
August 14, 2025	EX-10.18	First amendment to License Agreement between BioLargo, Inc., and Ikigai Holdings, LLC, dated August 16, 2021 Exhibit 10.18 DocuSign Envelope ID: 656651A6-A760-448C-BD4B-9E8550A59CC9 FIRST AMENDMENT TO LICENSE AGREEMENT This FIRST AMENDMENT TO LICENSE AGREEMENT (this “Amendment”), is dated August 16, 2021, and is by and between BioLargo, Inc., a Delaware corporation, and BioLargo Life Technologies, Inc., a California corporation (“Licensor”), and Ikigai Holdings, LLC, a Nevada limited liability company (“
August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-19709 BIO
August 14, 2025	EX-10.17	License Agreement between BioLargo, Inc., and Ikigai Holdings, LLC, dated May 17, 2021 Exhibit 10.17 LICENSE AGREEMENT [Pet Products] This License Agreement (the “Agreement”) is made this 17th day of May, 2021, by and between BioLargo, Inc., a Delaware corporation and its wholly owned subsidiary BioLargo Life Technologies, Inc., a California corporation, having a principal place of business at 14921 Chestnut Street, Westminster, California 92683 (collectively referred to as “Licenso
August 14, 2025	EX-10.19	Preferred Master Manufacturing Agreement between ONM Environmental, Inc., and Ikigai Holdings, LLC, dated July 9, 2021 Exhibit 10.19 PREFERRED MASTER MANUFACTURING AGREEMENT This Preferred Master Manufacturing Agreement (“Agreement”), dated as of July 9, 2021 (the “Effective Date”), is entered into by and between ONM Environmental, Inc., a California corporation, having a principal place of business at 14921 Chestnut Street, Westminster, California 92683(“Seller”), and Ikigai Holdings, LLC, a Nevada limited liabil
July 23, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numbe
July 23, 2025	EX-99.1	BioLargo Provides Review of 2025 Accomplishments and Insights for Coming Year EXHIBIT 99.1 - PRESS RELEASE BioLargo Provides Review of 2025 Accomplishments and Insights for Coming Year Letter to stockholders Westminster, CA – July 23, 2025 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, today provided a mid-year review of its business highlights for 2025 and a commentary
June 25, 2025	EX-99.1	BioLargo Announces Results of 2025 Annual Stockholder Meeting BioLargo Announces Results of 2025 Annual Stockholder Meeting No immediate intention to proceed with a reverse stock split – “This vote empowers us to be ready when the time is right.
June 25, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2025 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numbe
June 11, 2025	424B4	PROSPECTUS 34,888,449 shares of common stock Filed pursuant to Rule 424(b)(4) Registration No. 333-278669 PROSPECTUS 34,888,449 shares of common stock This prospectus relates to the offer and sale of up to 34,888,449 shares of common stock, par value $0.00067, of BioLargo, Inc., a Delaware corporation, by the selling stockholders identified herein (referred to collectively herein as the “selling stockholders,” or individually as a “selling s
June 5, 2025	POS AM	As filed with the Securities and Exchange Commission June 4, 2025 Table of Contents As filed with the Securities and Exchange Commission June 4, 2025 Registration No.
May 15, 2025	EX-99.1	Slide deck presentation Exhibit 99.1
May 15, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Number
May 15, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-19709 BI
May 14, 2025	POS AM	As filed with the Securities and Exchange Commission May 14, 2025 Table of Contents As filed with the Securities and Exchange Commission May 14, 2025 Registration No.
April 25, 2025	424B4	PROSPECTUS 25,507,789 shares of common stock Filed pursuant to Rule 424(b)(4) Registration No. 333-268973 PROSPECTUS 25,507,789 shares of common stock This prospectus relates to the offer and sale of up to 25,507,789 shares of common stock, par value $0.00067, of BioLargo, Inc., a Delaware corporation, by Lincoln Park Capital Fund, LLC, whom we refer to in this prospectus as “Lincoln Park” or the “selling stockholder.” The shares of common s
April 25, 2025	DEF 14A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy S
April 18, 2025	EX-99.1	Audit Committee charter BioLargo, Inc. Audit Committee Charter Role The Audit Committee of the Board of Directors assists the Board of Directors in fulfilling its responsibility for oversight of the quality and integrity of the accounting, auditing, and reporting practices of the Company, and such other duties as directed by the Board. The Committee’s purpose is to oversee the accounting and financial reporting processes
April 18, 2025	EX-99.2	Nomination and Corporation Governance Committee charter CHARTER OF THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE OF BIOLARGO, INC. Membership The Nominating and Corporate Governance Committee (the “Committee”) of the board of directors (the “Board”) of BioLargo, Inc., a Delaware corporation (the “Company”) shall consist of three or more directors. Each member of the Committee shall be independent in accordance with the rules of the NASDAQ Capital M
April 18, 2025	EX-99.3	Compensation Committee charter BIOLARGO, INC. COMPENSATION COMMITTEE CHARTER Role The Compensation Committee’s role is to discharge the Board’s responsibilities relating to compensation of the Company’s executives, to produce an annual report on executive compensation for inclusion in the Company’s proxy statement, and to oversee and advise the Board on the adoption of policies that govern the Company’s compensation programs, i
April 18, 2025	POS AM	As filed with the Securities and Exchange Commission on April 17, 2025 Table of Contents As filed with the Securities and Exchange Commission on April 17, 2025 Registration No.
April 18, 2025	EX-4.4	2024 Equity Incentive Plan BIOLARGO, INC. 2024 EQUITY INCENTIVE PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of BioLargo and Parents, Subsidiaries and Affiliates that exist now or in the future by offering them an opportunity to participate in BioLargo’s future performance through the
April 10, 2025	PRE 14A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S
March 31, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numb
March 31, 2025	EX-99.1	Slide deck presentation Exhibit 99.1
March 31, 2025	EX-99.2	Cleantech Innovator BioLargo Reports Record Revenues in 2024 Annual Report Exhibit 99.2 Cleantech Innovator BioLargo Reports Record Revenues in 2024 Annual Report Revenues up 45% over prior year Westminster, CA – April 1, 2025 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its Annual Report reported record revenues and an increase of 45% over prior yea
March 31, 2025	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation BioLargo Energy Technologies, Inc., a California corporation* BioLargo Equipment Solutions & Technologies, Inc., a California corporation BioLargo Canada, Inc., a Canadian corporation BioLargo Development Corp., a California corporation BioLar
March 31, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 15, 2024	EX-99.1	Slide deck presentation Exhibit 99.1
November 15, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File N
November 15, 2024	EX-99.2	BioLargo’s year-to-date revenues up 80% Annual revenue record secured, with one quarter remaining. Exhibit 99.2 BioLargo’s year-to-date revenues up 80% Annual revenue record secured, with one quarter remaining. Westminster, CA – November 15, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced results of its third quarter of 2024: ● Revenues ($14.1 million) through September 30, 20
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-1970
August 15, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Num
August 15, 2024	EX-99.1	Slide deck presentation Exhibit 99.1
August 14, 2024	EX-10.16	2024 Engagement Extension Agreement with CFO EXHIBIT 10.16 BioLargo, Inc. 2024 Engagement Extension Agreement This Engagement Extension Agreement dated August 13, 2024 (the “Extension”) references the Engagement Agreement and Scope Letter dated February 1, 2008 (“2008 Agreement”) by and between CFO 911 (Charles K. Dargan II) (the “Advisor)” and BioLargo, Inc. (the “Company”), and written extensions to the Agreement (the “Prior Extensions”),
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-19709 BIO
June 20, 2024	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numbe
June 13, 2024	EX-99.1	Presentation slides Exhibit 99.1
June 13, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numbe
May 15, 2024	EX-99.2	BioLargo Generates Positive Operating Cash Flow on Record Quarterly Revenues for First Quarter of 2024 Exhibit 99.2 BioLargo Generates Positive Operating Cash Flow on Record Quarterly Revenues for First Quarter of 2024 Westminster, CA – May 14, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that the company generated $481,000 operating cash flow with record quarterly revenues of
May 15, 2024	EX-99.1	Slide deck presentation Exhibit 99.1
May 15, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Number
May 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-19709 BI
April 26, 2024	DEF 14A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy S
April 25, 2024	424B4	17,683,826 shares of common stock Filed pursuant to Rule 424(b)(4) Registration No. 333-233534 PROSPECTUS 17,683,826 shares of common stock This prospectus relates to the offer and sale of up to 17,683,826 shares of common stock, par value $0.00067, of BioLargo, Inc., a Delaware corporation, by the selling stockholders identified herein (referred to collectively herein as the “selling stockholders,” or individually as a “selling s
April 25, 2024	424B4	34,888,449 shares of common stock Filed pursuant to Rule 424(b)(4) Registration No. 333-278669 PROSPECTUS 34,888,449 shares of common stock This prospectus relates to the offer and sale of up to 34,888,449 shares of common stock, par value $0.00067, of BioLargo, Inc., a Delaware corporation, by the selling stockholders identified herein (referred to collectively herein as the “selling stockholders,” or individually as a “selling s
April 25, 2024	424B4	PROSPECTUS 25,507,789 shares of common stock Filed pursuant to Rule 424(b)(4) Registration No. 333-268973 PROSPECTUS 25,507,789 shares of common stock This prospectus relates to the offer and sale of up to 25,507,789 shares of common stock, par value $0.00067, of Biolargo, Inc., a Delaware corporation, by Lincoln Park Capital Fund, LLC, whom we refer to in this prospectus as “Lincoln Park” or the “selling stockholder.” The shares of common s
April 19, 2024	CORRESP	BioLargo, Inc. BioLargo, Inc. 14921 Chestnut St. Westminster, CA 92683 Telephone: 888.400.2863 Facsimile: 949.625.9819 April 19, 2024 U.S. Securities & Exchange Commission Division of Corporation Finance 100 F. Street NE Washington, D.C. 20549 Re: BioLargo, Inc. Registration Statement on Form S-1 Filed April 12, 2024 File No. 333-278669 REQUEST FOR ACCELERATION OF EFFECTIVENESS Ladies and Gentlemen: Pursuant to
April 15, 2024	POS EX	As filed with the Securities and Exchange Commission on April 15, 2024 As filed with the Securities and Exchange Commission on April 15, 2024 Registration No.
April 15, 2024	POS EX	As filed with the Securities and Exchange Commission on April 15, 2024 As filed with the Securities and Exchange Commission on April 15, 2024 Registration No.
April 12, 2024	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation BioLargo Energy Technologies, Inc., a California corporation* BioLargo Equipment Solutions & Technologies, Inc., a California corporation BioLargo Canada, Inc., a Canadian corporation BioLargo Development Corp., a California corporation BioLar
April 12, 2024	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation BioLargo Energy Technologies, Inc., a California corporation* BioLargo Equipment Solutions & Technologies, Inc., a California corporation BioLargo Canada, Inc., a Canadian corporation BioLargo Development Corp., a California corporation BioLar
April 12, 2024	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation BioLargo Energy Technologies, Inc., a California corporation* BioLargo Equipment Solutions & Technologies, Inc., a California corporation BioLargo Canada, Inc., a Canadian corporation BioLargo Development Corp., a California corporation BioLar
April 12, 2024	POS AM	As filed with the Securities and Exchange Commission on April 12, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 12, 2024 Registration No.
April 12, 2024	POS AM	As filed with the Securities and Exchange Commission on April 12, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 12, 2024 Registration No.
April 12, 2024	EX-FILING FEES	Calculation of registration fee Exhibit 107.1 CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(1) Equity Common stock, par value $0.00067 457(o) 34,888,449(2) $ 0.2586 $9,022,461.00 0.0001476 $1,331.72 Total offering amounts: $9,022,461.00 $1,331.72 Total fees
April 12, 2024	S-1	As filed with the Securities and Exchange Commission April 12, 2024 Table of Contents As filed with the Securities and Exchange Commission April 12, 2024 Registration No.
April 5, 2024	RW	April 5, 2024 BioLargo, Inc. 14921 Chestnut St. Westminster, CA 92683 Telephone: 888.400.2863 Facsimile: 949.625.9819 April 5, 2024 U.S. Securities & Exchange Commission Division of Corporate Finance 100 F. Street NE Washington, D.C. 20549 Attn: Jessica Ansart Re: BioLargo, Inc. Registration Statement on Form S-1 Filed April 27, 2023 File No. 333-271465 Ladies and Gentlemen: On April 27, 2023, BioLargo, Inc. (t
April 1, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 1, 2024	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation BioLargo Energy Technologies, Inc., a California corporation* BioLargo Equipment Solutions & Technologies, Inc., a California corporation BioLargo Canada, Inc., a Canadian corporation BioLargo Development Corp., a California corporation BioLar
April 1, 2024	EX-10.1	BioLargo license to Clyra Medical Technologies, Inc., dated March 1, 2024 EXHIBIT 10.1 LICENSE AGREEMENT (BioLargo to Clyra) This License Agreement (the “Agreement”) is made this 1st day of March, 2024, by and between BioLargo, Inc., a Delaware corporation and its wholly owned subsidiary BioLargo Life Technologies, Inc., a California corporation, having a principal place of business at 14921 Chestnut St., Westminster, California 92683 (collectively referred to as “Licen
April 1, 2024	EX-10.2	Clyra Medical Technologies, Inc. license to BioLargo dated March 1, 2024 EXHIBIT 10.2 LICENSE AGREEMENT (Clyra to BioLargo) This License Agreement (the “Agreement”) is made this 1st day of March, 2024, by and between BioLargo, Inc., a Delaware corporation and its wholly owned subsidiary BioLargo Life Technologies, Inc., a California corporation, having a principal place of business at 14921 Chestnut St., Westminster, California 92683 (collectively referred to as “Licen
January 22, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Nu
January 22, 2024	EX-99.1	BioLargo Doubles Annual Revenues - Again Exhibit 99.1 BioLargo Doubles Annual Revenues - Again Westminster, CA – January 22, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its annual revenues for the year ended December 31, 2023, were more than double 2022 revenues, representing the second year in a row revenues h
January 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Nu
January 10, 2024	EX-99.1	Slide deck presentation Exhibit 99.1
January 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 BioLargo, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Num
January 5, 2024	EX-16.1	Letter from Haskell & White LLP to the Securities and Exchange Commission dated January 3, 2024 Exhibit 16.1 January 3, 2024 Office of the Chief Accountant U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read the statements under Item 4.01 of the Current Report on Form 8-K of BioLargo, Inc. to be filed with the Securities and Exchange Commission on or about January 5, 2024. We agree with all statements pertaining to us. We have no
November 21, 2023	EX-99.1	Slide deck presentation Exhibit 99.1
November 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File N
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-1970
October 4, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Num
October 4, 2023	EX-99.1	Slide deck presentation Exhibit 99.1
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-19709 BIO
June 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Number
June 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Number
June 9, 2023	EX-99.1	END Exhibit 99.1 Dennis Calvert: Okay, good morning ladies and gentlemen. It's now 10:13 AM. Annual Meeting of Stockholders, BioLargo please come to order. I'm Dennis Calvert. Make sure I got my ringer off. Everybody got the ringer off. That'll be helpful. I'm Dennis Calvert. Present chairman of the board of the company. We welcome you and want to express our thanks for your attendance at this meeting
June 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Number
June 6, 2023	EX-99.1	Presentation slides Exhibit 99.1
May 23, 2023	424B4	PROSPECTUS 22,689,035 shares of common stock Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-233534 Dated: May 10, 2023 PROSPECTUS 22,689,035 shares of common stock This prospectus relates to the offer and sale of up to 22,689,035 shares of common stock, par value $0.00067, of BioLargo, Inc., a Delaware corporation, by the selling stockholders identified herein (referred to collectively herein as the “selling stockhol
May 18, 2023	EX-99.1	Slide deck presentation Exhibit 99.1
May 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Number
May 17, 2023	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation BioLargo Equipment Solutions & Technologies, Inc., a California corporation BioLargo Water, Inc., a Canadian corporation BioLargo Development Corp., a California corporation BioLargo Engineering, Science & Technologies, LLC, a Tennessee limite
May 17, 2023	EX-10.21	Form of Share Exchange Agreement between BioLargo, Inc., and purchasers of BioLargo Energy Technologies, Inc. common stock Ex. 10.21 SHARE EXCHANGE AGREEMENT THIS SHARE EXCHANGE AGREEMENT (“Agreement”) is made and entered into as of , by and between BioLargo Energy Technologies, Inc., a California corporation (“BET”), BioLargo, Inc., a Delaware corporation (“BioLargo”), and (“Investor”), with respect to the following: R E C I T A L S : A. BET accepted an investment from Investor in its private securities offering date
May 17, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-19709 BI
May 17, 2023	EX-10.20	Form of Share Exchange Agreement between BioLargo, Inc., and purchasers of Clyra Medical Series A Preferred Stock Ex. 10.20 SHARE EXCHANGE AGREEMENT THIS SHARE EXCHANGE AGREEMENT (“Agreement”) is made and entered into as of , by and between Clyra Medical Technologies, Inc., a California corporation (“Clyra”), BioLargo, Inc., a Delaware corporation (“BioLargo”), and (“Investor”), with respect to the following: R E C I T A L S : A. Clyra accepted an investment from Investor in its October 2022 Preferred Unit Of
May 16, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: ===
May 9, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Number)
May 9, 2023	POS EX	As filed with the Securities and Exchange Commission on May 9, 2023 As filed with the Securities and Exchange Commission on May 9, 2023 Registration No.
May 9, 2023	EX-99.1	0:00:04.0 Speaker 1: Exhibit 99.1 [music] 0:00:04.0 Speaker 1: Dennis, welcome back. 0:00:05.7 Dennis Calvert: Today. What's up? Dennis Calvert. 0:00:08.6 S1: How are ya? 0:00:10.2 DC: Life is so good I have to pinch myself. [laughter] 0:00:14.0 S1: Amen to that. Look, we've got a lot of things to talk about to dive into the deep nitty-gritty things, but before we start though, for the folks that may not have heard ou
April 27, 2023	POS AM	As filed with the Securities and Exchange Commission on April 26, 2023 Table of Contents As filed with the Securities and Exchange Commission on April 26, 2023 Registration No.
April 27, 2023	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation BioLargo Energy Technologies, Inc., a California corporation* BioLargo Equipment Solutions & Technologies, Inc., a California corporation BioLargo Water, Inc., a Canadian corporation BioLargo Development Corp., a California corporation BioLarg
April 27, 2023	S-1	As filed with the Securities and Exchange Commission on April 26, 2023 Table of Contents As filed with the Securities and Exchange Commission on April 26, 2023 Registration No.
April 27, 2023	EX-FILING FEES	Calculation of registration fee Exhibit 107 CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(1) Equity Common stock, par value $0.
April 27, 2023	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation BioLargo Energy Technologies, Inc., a California corporation* BioLargo Equipment Solutions & Technologies, Inc., a California corporation BioLargo Water, Inc., a Canadian corporation BioLargo Development Corp., a California corporation BioLarg
April 24, 2023	424B4	29,570,000 shares of common stock 424B4 1 blgo20230424424b4.htm FORM 424B4 Prospectus Filed pursuant to Rule 424(b)(4) Registration No. 333-268973 29,570,000 shares of common stock This prospectus relates to the offer and sale of up to 29,570,000 shares of common stock, par value $0.00067, of Biolargo, Inc., a Delaware corporation, by Lincoln Park Capital Fund, LLC, whom we refer to in this prospectus as “Lincoln Park” or the “sel
April 21, 2023	DEF 14A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy S
April 14, 2023	EX-FILING FEES	Calculation of registration fee Exhibit 107.1 CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(2) Equity Common stock, par value $0.00067 457(c) 29,454,597 $ 0.336 $9,895,193 0.0001102 $ 1,090.45 (1) Estimated solely for the purpose of calculating the registrat
April 14, 2023	POS AM	As filed with the Securities and Exchange Commission on April 14, 2023 Table of Contents As filed with the Securities and Exchange Commission on April 14, 2023 Registration No.
April 14, 2023	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation BioLargo Energy Technologies, Inc., a California corporation* BioLargo Equipment Solutions & Technologies, Inc., a California corporation BioLargo Water, Inc., a Canadian corporation BioLargo Development Corp., a California corporation BioLarg
April 4, 2023	EX-99.1	Slide deck presentation EX-99.1 2 ex496962.htm EXHIBIT 99.1 Exhibit 99.1
April 4, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numbe
March 31, 2023	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation BioLargo Energy Technologies, Inc., a California corporation BioLargo Equipment Solutions & Technologies, Inc., a California corporation BioLargo Water, Inc., a Canadian corporation BioLargo Development Corp., a California corporation BioLargo
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-19
March 31, 2023	EX-4.19	Satisfaction of March 2018 $50,000 Convertible Note, dated March 6, 2023 Exhibit 4.19 Satisfaction of Promissory Note THIS SATISFACTION OF PROMISSORY NOTE (the “Satisfaction”) is entered into as of March 6, 2023 (the “Effective Date”), by and among BioLargo, Inc., a Delaware corporation (“BioLargo”), and Bruce Kelber (“Kelber”), with reference to the following described “Note”: Issuance Date: March 8, 2018 Maturity Date: March 1, 2023 Note No. 33097 Principal Amount: $
March 31, 2023	EX-3.5	Amended and Restated Articles of Incorporation of Clyra Medical Technologies, Inc. (filed December 30, 2022) Exhibit 3.5 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF CLYRA MEDICAL TECHNOLOGIES, INC. ARTICLE I: The name of this corporation is Clyra Medical Technologies, Inc. (the “Corporation”). ARTICLE II: The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of California other than the banking business,
March 31, 2023	EX-10.23	Form of indemnity agreement between the Company at its officers and directors Exhibit 10.23 FORM OF INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , by and between BioLargo, Inc., a Delaware corporation (the “Company”), and the undersigned officers and directors of the Company (each, individually, an “Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as
March 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numb
March 27, 2023	EX-10.3	2023 Engagement Extension Agreement with CFO Exhibit 10.3 BioLargo, Inc. 2023 Engagement Extension Agreement This Engagement Extension Agreement (the “Extension”) references the Engagement Agreement and Scope Letter dated February 1, 2008 (“2008 Agreement”) by and between CFO 911 (Charles K. Dargan II) (the “Advisor)” and BioLargo, Inc. (the “Company”), and written extensions to the Agreement (the “Prior Extensions”), pursuant to which Charl
March 20, 2023	EX-99.1	BioLargo Continues Record Setting Revenue Growth Exhibit 99.1 BioLargo Continues Record Setting Revenue Growth Westminster, CA – March 20, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that the Company’s first quarter 2023 revenues have already surpassed the Company’s previous record quarterly revenues set last quarter. This revenue growth is dr
March 20, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numb
January 26, 2023	424B4	PROSPECTUS 31,250,000 shares of common stock Filed pursuant to Rule 424(b)(4) Registration No. 333-268973 PROSPECTUS Dated: January 19, 2023 PROSPECTUS 31,250,000 shares of common stock This prospectus relates to the offer and sale of up to 31,250,000 shares of common stock, par value $0.00067, of Biolargo, Inc., a Delaware corporation, by Lincoln Park Capital Fund, LLC, whom we refer to in this prospectus as “Lincoln Park” or the “selling s
January 17, 2023	CORRESP	January 17, 2023 CORRESP 1 filename1.htm BioLargo, Inc. 14921 Chestnut St. Westminster, CA 92683 Telephone: 888.400.2863 Facsimile: 949.625.9819 January 17, 2023 U.S. Securities & Exchange Commission Division of Corporation Finance 100 F. Street NE Washington, D.C. 20549 Re: BioLargo, Inc. Registration Statement on Form S-1 Filed December 23, 2022 File No. 333-268973 REQUEST FOR ACCELERATION OF EFFECTIVENESS Ladie
January 11, 2023	S-1/A	As filed with the Securities and Exchange Commission on January 11, 2023 As filed with the Securities and Exchange Commission on January 11, 2023 Registration No.
January 11, 2023	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation Clyra Medical Technologies, Inc., a California corporation* BioLargo Equipment Solutions & Technologies, Inc., a California corporation BioLargo Water Investment Group, Inc., a California corporation BioLargo Water, Inc., a Canadian corporatio
January 11, 2023	EX-FILING FEES	Calculation of registration fee Exhibit 107 CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(2) Equity Common stock, par value $0.
January 6, 2023	CORRESP	January 6, 2023 CORRESP 1 filename1.htm BioLargo, Inc. 14921 Chestnut St. Westminster, CA 92683 Telephone: 888.400.2863 Facsimile: 949.625.9819 January 6, 2023 Jordan Nimitz U.S. Securities & Exchange Commission Division of Corporate Finance 100 F. Street NE Washington, D.C. 20549 Re: BioLargo, Inc. Registration Statement on Form S-1 Filed December 23, 2022 File No. 333-268973 WITHDRAWAL OF REQUEST FOR ACCELERATI
January 4, 2023	CORRESP	January 4, 2023 CORRESP 1 filename1.htm BioLargo, Inc. 14921 Chestnut St. Westminster, CA 92683 Telephone: 888.400.2863 Facsimile: 949.625.9819 January 4, 2023 U.S. Securities & Exchange Commission Division of Corporation Finance 100 F. Street NE Washington, D.C. 20549 Re: BioLargo, Inc. Registration Statement on Form S-1 Filed December 23, 2022 File No. 333-268973 REQUEST FOR ACCELERATION OF EFFECTIVENESS Ladies
December 23, 2022	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation Clyra Medical Technologies, Inc., a California corporation* BioLargo Water Investment Group, Inc., a California corporation BioLargo Water, Inc., a Canadian corporation** BioLargo Development Corp., a California corporation BioLargo Engineerin
December 23, 2022	S-1	As filed with the Securities and Exchange Commission on December 22, 2022 As filed with the Securities and Exchange Commission on December 22, 2022 Registration No.
December 23, 2022	EX-FILING FEES	Calculation of registration fee Exhibit 107 CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Common stock, par value $0.
December 19, 2022	EX-10.1	Purchase Agreement, dated as of December 13, 2022, by and between BioLargo, Inc. and Lincoln Park Capital Fund, LLC. Exhibit 10.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of December 13, 2022, by and between BIOLARGO, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor w
December 19, 2022	EX-4.1	Registration Rights Agreement, dated as of December 13, 2022, by and between BioLargo, Inc. and Lincoln Park Capital Fund, LLC Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of December 13, 2022, by and between BIOLARGO, INC., a Delaware corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the res
December 19, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 BioLargo, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File N
November 14, 2022	EX-3.4	Certificate of Amendment to Certificate of Incorporation, filed August 30, 2022 Exhibit 3.4 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF BIOLARGO, INC. BioLargo, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows: FIRST, that the Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-1970
November 3, 2022	EX-10.1	Form of Board Member Agreement Exhibit 10.1 [FORM OF] BOARD OF DIRECTORS AGREEMENT (INDEPENDENT DIRECTORS) THIS AGREEMENT is made by and between BioLargo, Inc., a Delaware corporation (the ?Company?) with its principal place of business located at 14921 Chestnut Street, Westminster, CA 92683, and , an individual (?Director?). 1. Effective Date This Agreement shall commence as of the date Director is appointed or elected to the
November 3, 2022	EX-99.1	BioLargo Adds Linda Park and Christina Bray to Board of Directors Exhibit 99.1 BioLargo Adds Linda Park and Christina Bray to Board of Directors Westminster, CA ? November 3, 2022 ? BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced it has added two new board members to its team: Linda Park and Christina Bray. Both new board members have a background, education, and corpora
November 3, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Nu
November 3, 2022	EX-10.2	Form of Indemnity Agreement Exhibit 10.2 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of November 1, 2022, by and between BioLargo, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided with adequa
October 31, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Nu
October 31, 2022	EX-99.1	BioLargo Sets Another New Quarterly Revenue Record Exhibit 99.1 BioLargo Sets Another New Quarterly Revenue Record Westminster, CA – October 26, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, today announced that it has set a new quarterly revenue record, and provided a snapshot of continued business developments. BioLargo’s President and CEO Dennis P. Calve
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022. or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-19709 BIO
August 5, 2022	EX-99.1	BioLargo Sets New Quarterly Revenue Record Exhibit 99.1 BioLargo Sets New Quarterly Revenue Record Quarterly revenues in Q2 grew 37% compared to Q1, and 185% compared to Q2 of 2021. Westminster, CA ? August 3, 2022 ? BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, today announced that it has set a new quarterly revenue record, and provided a snapshot of the
August 5, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numb
June 7, 2022	EX-3.1	Certificate of Amendment to Certificate of Incorporation, dated June 6, 2022 Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF BIOLARGO, INC. BioLargo, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), hereby certifies as follows: FIRST, that the Corporation?s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on
June 7, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders -12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File
June 2, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Number
June 2, 2022	EX-99.1	Presentation slides Exhibit 99.1
May 19, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Number
May 19, 2022	EX-99.1	BioLargo’s First Quarterly Report of 2022 Highlights: Record Company-wide Revenues, Subsidiaries Achieving and Approaching Profitability, and Progress of Key Growth Catalysts EX-99.1 2 ex378157.htm EXHIBIT 99.1 Exhibit 99.1 BioLargo’s First Quarterly Report of 2022 Highlights: Record Company-wide Revenues, Subsidiaries Achieving and Approaching Profitability, and Progress of Key Growth Catalysts Westminster, CA – May 17, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Qu
May 19, 2022	EX-99.2	Presentation slides Exhibit 99.2
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022. or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-19709 BI
April 22, 2022	424B4	PROSPECTUS 36,090,857 shares of common stock 424B4 1 blgo20220422d424b4.htm FORM 424B4 Table of Contents April 22, 2022 Filed pursuant to Rule 424(b)(4) Registration No. 333-215730 PROSPECTUS 36,090,857 shares of common stock This prospectus relates to the sale of up to 36,090,857 shares of our common stock by persons who have purchased shares in a series of private placements. The aforementioned persons are sometimes referred to in this pro
April 22, 2022	424B4	PROSPECTUS 4,589,694 shares of common stock Dated: April 22, 2022 Filed pursuant to Rule 424(b)(4) Registration No. 333-237651 PROSPECTUS 4,589,694 shares of common stock This prospectus relates to the offer and sale of up to 4,589,694 shares of common stock, par value $0.00067, of Biolargo, Inc., a Delaware corporation, by Lincoln Park Capital Fund, LLC, whom we refer to in this prospectus as ?Lincoln Park? or the ?selling stockholder.? Th
April 22, 2022	424B4	PROSPECTUS 25,241,369 shares of common stock Table of Contents April 22, 2022 Filed pursuant to Rule 424(b)(4) Registration No.
April 20, 2022	EX-99.1	BioLargo Continues Growth Trend by Breaking Quarterly Revenue Record Exhibit 99.1 BioLargo Continues Growth Trend by Breaking Quarterly Revenue Record Westminster, CA ? April 20, 2022 ? BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, today announced a company-wide quarterly revenue record for the first quarter of 2022. The company also announced it had been awarded the initial contra
April 20, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2022 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numb
April 18, 2022	DEF 14A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 DEF 14A 1 blgo20220415cdef14a.htm FORM DEF 14A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-
April 14, 2022	POS AM	As filed with the Securities and Exchange Commission on April 13, 2022 POS AM 1 blgo20220412posam.htm POS AM Table of Contents As filed with the Securities and Exchange Commission on April 13, 2022 Registration No. 333-233534 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOLARGO, INC. (Exact name of registrant as specified in its charter) Delawa
April 14, 2022	POS AM	As filed with the Securities and Exchange Commission on April 13, 2022 Table of Contents As filed with the Securities and Exchange Commission on April 13, 2022 Registration No.
April 14, 2022	POS AM	As filed with the Securities and Exchange Commission on April 13, 2022 POS AM 1 blgo20220411posam.htm POS AM As filed with the Securities and Exchange Commission on April 13, 2022 Registration No. 333-237651 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOLARGO, INC. (Exact name of registrant as specified in its charter) Delaware 2800 65-0159115
April 4, 2022	EX-99.1	BioLargo Annual Report for 2021 Highlights Active Commercial Catalysts, Expanding Partnerships, and Improved Balance Sheet Exhibit 99.1 BioLargo Annual Report for 2021 Highlights Active Commercial Catalysts, Expanding Partnerships, and Improved Balance Sheet Westminster, CA ? March 31, 2022 ? BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Annual Report on Form 10-K with the SEC today for the year ended December 31, 2021 (www.
April 4, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numb
April 4, 2022	EX-99.2	Presentation slides Exhibit 99.2
April 4, 2022	PRE 14A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 PRE 14A 1 blgo20220404pre14a.htm FORM PRE 14A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6
March 31, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-19
March 31, 2022	EX-21.1	List of Subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California corporation ONM Environmental, Inc., a California corporation Clyra Medical Technologies, Inc., a California corporation* BioLargo Water Investment Group, Inc., a California corporation BioLargo Water, Inc., a Canadian corporation** BioLargo Development Corp., a California corporation BioLargo Engineerin
March 24, 2022	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2022 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numb
March 24, 2022	EX-10.3	2022 Engagement Extension Agreement with CFO Exhibit 10.3 BioLargo, Inc. 2022 Engagement Extension Agreement This Engagement Extension Agreement (the ?Extension?) references the Engagement Agreement and Scope Letter dated February 1, 2008 (?2008 Agreement?) by and between CFO 911 (Charles K. Dargan II) (the ?Advisor)? and BioLargo, Inc. (the ?Company?), and written extensions to the Agreement (the ?Prior Extensions?), pursuant to which Charl
March 8, 2022	EX-10.5	Agreement dated March 1, 2022, by and between Scion Solutions, LLC, Clyra Medical Technologies, Inc., and BioLargo, Inc Exhibit 10.5 AGREEMENT THIS AGREEMENT (?Agreement?) is made and entered into as of this 1st day of March, 2022 (the ?Effective Date?), by and between Clyra Medical Technologies, Inc., a California corporation (?Clyra?), BioLargo, Inc., a Delaware corporation (?BioLargo?), Scion Solutions, LLC, an Indiana limited liability company (?Scion?), the undersigned members of Scion (?Scion Members?), and f
March 8, 2022	EX-10.6	Agreement dated March 1, 2022, by and between Clyra Medical Technologies, Inc., and BioLargo, Inc. Exhibit 10.6 AGREEMENT THIS AGREEMENT (?Agreement?) is made and entered into as of this 3rd day of March, 2022, by and between Clyra Medical Technologies, Inc., a California corporation (?Clyra?), and BioLargo, Inc., a Delaware corporation (?BioLargo?), with respect to the following: R E C I T A L S : A. Clyra, BioLargo, and Scion Solutions, LLC (?Scion?), are parties to a series of agreements (th
March 8, 2022	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numbe
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021. or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-1970
August 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-19709 BIO
June 17, 2021	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 blgo202106168k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of inc
June 15, 2021	EX-99.1	Presentation slides Exhibit 99.1
June 15, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numbe
May 19, 2021	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Number
May 19, 2021	EX-4.11	Final Payoff Agreement dated May 17, 2021 to Promissory Note issued to Vernal Bay Investments, LLC on September 19, 2018 Exhibit 4.11 FINAL PAYOFF AGREEMENT TO THE PROMISSORY NOTE DATED SEPTEMBER 19, 2018 THIS FINAL PAYOFF AGREEMENT TO THE PROMISSORY NOTE DATED SEPTEMBER 19, 2018 (?Agreement?) is made and entered into as of this May 17, 2021, by and between BIOLARGO, INC., a Delaware corporation (?Issuer?), and VERNAL BAY INVESTMENTS, LLC (the ?Holder?), with respect to the following: WHEREAS, Issuer issued to Holde
May 19, 2021	EX-4.07	Second Amendment dated August 12, 2019, to Promissory Note issued to Chappy Bean, LLC dated September 19, 2018 Exhibit 4.07 SECOND AMENDMENT TO THE PROMISSORY NOTE DATED SEPTEMBER 19, 2018 THIS SECOND AMENDMENT TO THE PROMISSORY NOTE DATED SEPTEMBER 19, 2018 (?Amendment?) is made and entered into as of this August 16, 2019 by and between BIOLARGO, INC., a Delaware corporation (?Issuer?), and Chappy Bean, LLC (the ?Holder?), with respect to the following: WHEREAS, Issuer issued to Holder a 12% Promissory No
May 19, 2021	EX-4.09	Third Amendment dated August 10, 2020 to Promissory Note issued to Vernal Bay Investments, LLC on September 19, 2018 Exhibit 4.09 THIRD AMENDMENT TO THE PROMISSORY NOTE DATED SEPTEMBER 19, 2018 THIS THIRD AMENDMENT TO THE PROMISSORY NOTE DATED SEPTEMBER 19, 2018 (?Amendment?) is made and entered into as of this August 10, 2020, by and between BIOLARGO, INC., a Delaware corporation (?Issuer?), and VERNAL BAY INVESTMENTS, LLC (the ?Holder?), with respect to the following: WHEREAS, Issuer issued to Holder a 12% Pro
May 19, 2021	EX-4.12	Final Payoff Agreement dated May 18, 2021 to Promissory Note issued to Chappy Bean, LLC dated September 19, 2018 Exhibit 4.12 FINAL PAYOFF AGREEMENT TO THE PROMISSORY NOTE DATED SEPTEMBER 19, 2018 THIS FINAL PAYOFF AGREEMENT TO THE PROMISSORY NOTE DATED SEPTEMBER 19, 2018 (?Agreement?) is made and entered into as of this May 18, 2021, by and between BIOLARGO, INC., a Delaware corporation (?Issuer?), and CHAPPY BEAN, LLC (the ?Holder?), with respect to the following: WHEREAS, Issuer issued to Holder a 12% Pro
May 19, 2021	EX-4.10	Third Amendment dated August 10, 2020, to Promissory Note issued to Chappy Bean, LLC dated September 19, 2018 EX-4.10 5 ex251823.htm EXHIBIT 4.10 Exhibit 4.10 THIRD AMENDMENT TO THE PROMISSORY NOTE DATED SEPTEMBER 19, 2018 THIS THIRD AMENDMENT TO THE PROMISSORY NOTE DATED SEPTEMBER 19, 2018 (“Amendment”) is made and entered into as of this August 10, 2020, by and between BIOLARGO, INC., a Delaware corporation (“Issuer”), and Chappy Bean, LLC (the “Holder”), with respect to the following: WHEREAS, Issuer i
May 19, 2021	EX-4.08	Amended and restated note issued to Chappy Bean on August 12, 2019 Exhibit 4.08 CONVERTIBLE PROMISSORY NOTE THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?) OR APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS
May 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-19709 BI
April 22, 2021	DEF 14A	- FORM DEF 14A Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy S
April 13, 2021	424B4	PROSPECTUS 18,290,084 shares of common stock April 12 Filed pursuant to Rule 424(b)(4) Registration No. 333-237651 PROSPECTUS 18,290,084 shares of common stock This prospectus relates to the offer and sale of up to 18,290,084shares of common stock, par value $0.00067, of Biolargo, Inc., a Delaware corporation, by Lincoln Park Capital Fund, LLC, whom we refer to in this prospectus as “Lincoln Park” or the “selling stockholder.” The shares of
April 12, 2021	424B4	PROSPECTUS 36,090,857 shares of common stock April 12 Filed pursuant to Rule 424(b)(4) Registration No. 333-215730 PROSPECTUS 36,090,857 shares of common stock This prospectus relates to the sale of up to 36,090,857 shares of our common stock by persons who have purchased shares in a series of private placements. The aforementioned persons are sometimes referred to in this prospectus as the selling stockholders. The shares offered under this
April 12, 2021	424B4	PROSPECTUS 26,669,650 shares of common stock April 12 Filed pursuant to Rule 424(b)(4) Registration No. 333-233534 PROSPECTUS 26,669,650 shares of common stock This prospectus relates to the offer and sale of up to 26,669,650 shares of common stock, par value $0.00067, of BioLargo, Inc., a Delaware corporation, by the selling stockholders identified herein (referred to collectively herein as the ?selling stockholders,? or individually as a ?
April 12, 2021	424B4	PROSPECTUS 13,801,119 shares of common stock Filed pursuant to Rule 424(b)(4) Registration No. 333-222572 PROSPECTUS 13,801,119 shares of common stock This prospectus relates to the offer and sale of up to 13,801,119 shares of common stock, par value $0.00067, of BioLargo, Inc., a Delaware corporation, by (i) Vista Capital Investments, LLC (?Vista Capital?), (ii) FirstFire Global Opportunities Fund, LLC (?FirstFire?), (iii) Black Mountain Eq
April 8, 2021	POS AM	- FORM POS AM POS AM 1 blgo20210406dposam.htm FORM POS AM Table of Contents As filed with the Securities and Exchange Commission on April 7, 2021 Registration No. 333-237651 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOLARGO, INC. (Exact name of registrant as specified in its charter) D
April 7, 2021	POS AM	- FORM POS AM POS AM 1 blgo20210406bposam.htm FORM POS AM Table of Contents As filed with the Securities and Exchange Commission on April 7, 2021 Registration No. 333-233534 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOLARGO, INC. (Exact name of registrant as specified in its charter) D
April 7, 2021	POS AM	- FORM POS AM POS AM 1 blgo20210406posam.htm FORM POS AM Table of Contents As filed with the Securities and Exchange Commission on April 7, 2021 Registration No. 333-215730 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOLARGO, INC. (Exact name of registrant as specified in its charter) De
April 7, 2021	POS AM	- FORM POS AM POS AM 1 blgo20210406cposam.htm FORM POS AM Table of Contents As filed with the Securities and Exchange Commission on April 7, 2021 Registration No. 333-222572 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOLARGO, INC. (Exact name of registrant as specified in its charter) D
April 2, 2021	PRE 14A	- FORM PRE 14A PRE 14A 1 blgo20210325pre14a.htm FORM PRE 14A Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi
March 31, 2021	EX-99.2	BioLargo 2020 Annual Report Highlights Expanding Commercial Traction for its Cleantech Technologies, Record Revenue Growth and Improved Balance Sheet EX-99.2 3 ex238397.htm EXHIBIT 99.2 Exhibit 99.2 BioLargo 2020 Annual Report Highlights Expanding Commercial Traction for its Cleantech Technologies, Record Revenue Growth and Improved Balance Sheet Westminster, CA – March 31, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Annual Report on Form 10-
March 31, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numb
March 31, 2021	EX-99.3	Presentation slides EX-99.3 4 ex238398.htm EXHIBIT 99.3 Exhibit 99.3
March 31, 2021	EX-99.1	BioLargo Year End 2020 Earnings Results Webcast and Conference Call Wednesday, March 31, 2021 - 5:00 PM Eastern Time EX-99.1 2 ex238396.htm EXHIBIT 99.1 Exhibit 99.1 BioLargo Year End 2020 Earnings Results Webcast and Conference Call Wednesday, March 31, 2021 - 5:00 PM Eastern Time Westminster, CA – March 30, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable clean- technologies and full-service environmental engineering company to host investor webcast and conference call on Wednesday March 31, 2021
March 30, 2021	EX-21.1	List of Subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California Corporation ONM Environmental, Inc., a California Corporation Clyra Medical Technologies, Inc., a California Corporation* BioLargo Water Investment Group, Inc., a California Corporation BioLargo Water, Inc., a Canadian Corporation** BioLargo Development Corp., a California Corporation BioLargo Engineerin
March 30, 2021	EX-4.49	Amendment to $50,000 Convertible Note dated March 8, 2018 EX-4.49 2 ex237877.htm EXHIBIT 4.49 Exhibit 4.49 Amendment to Promissory Note THIS AMENDMENT TO PROMISSORY NOTE (the “Amendment”) is entered into as of March 1, 2021 (the “Effective Date”), by and among BioLargo, Inc., a Delaware corporation (“BioLargo”), and Bruce Kelber (“Kelber”), with reference to the following described “Note”: Issuance Date: March 8, 2018 Maturity Date: none – demand note No
March 30, 2021	EX-4.50	Warrant issued to $50,000 Convertible Noteholder on March 1, 2020 Exhibit 4.50 BIOLARGO, INC. WARRANT TO PURCHASE COMMON STOCK THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE SECURITIES ACT AND APPLICABLE ST
March 30, 2021	10-K	Annual Report - FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-19
March 19, 2021	8-K	Financial Statements and Exhibits 8-K 1 blgo202103188k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of in
March 19, 2021	EX-10.3	2021 Engagement Extension Agreement with CFO Exhibit 10.3 BioLargo, Inc. 2021 Engagement Extension Agreement This Engagement Extension Agreement (the ?Extension?) references the Engagement Agreement and Scope Letter dated February 1, 2008 (?2008 Agreement?) by and between CFO 911 (Charles K. Dargan II) (the ?Advisor)? and BioLargo, Inc. (the ?Company?), and written extensions to the Agreement (the ?Prior Extensions?), pursuant to which Charl
March 5, 2021	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numbe
January 25, 2021	EX-99.1	Record Revenue in 2020 EX-99.1 2 ex222245.htm EXHIBIT 99.1 Exhibit 99.1 BioLargo Generates Record Revenue in 2020 President and CEO Dennis P. Calvert to highlight significant growth opportunities at upcoming investor conference this Tuesday, January 26th, 2021. Westminster, CA – January 25, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and a full-service environmental engineering company, t
January 25, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Nu
December 21, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2020 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File N
December 21, 2020	EX-99.1	Report Record EX-99.1 2 ex218597.htm EXHIBIT 99.1 Exhibit 99.1 BioLargo to Report Record Revenues in Fourth Quarter of 2020 Westminster, CA – December 21, 2020 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and a full-service environmental engineering company, today announced that its current fourth quarter revenues of approximately $750,000 will result in new quarterly and annual record
November 16, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-1970
August 14, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-19709 BIO
August 14, 2020	EX-4.22	Warrant issued in 2020 Unit Offering EX-4.22 2 ex199467.htm EXHIBIT 4.22 Exhibit 4.22 [FORM OF UNIT OFFERING WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNE
August 4, 2020	EX-99.1	BioLargo sales climb as balance sheet improves EX-99.1 2 ex196865.htm EXHIBIT 99.1 Exhibit 99.1 BioLargo sales climb as balance sheet improves Westminster, CA – August 4, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced today that company-wide sales in July had more than doubled its historical monthly average. Led by subsidiary Clyra Medical’s introduction
August 4, 2020	8-K	Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numb
July 28, 2020	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2020 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numbe
July 20, 2020	DEFA14A	- FORM DEFA14A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definit
July 7, 2020	EX-10.8	Revolving Line of Credit Note issued by Clyra Medical to Vernal Bay on June 30, 2020 EX-10.8 6 ex193297.htm EXHIBIT 10.8 Exhibit 10.8 REVOLVING LINE OF CREDIT NOTE FOR VALUE RECEIVED, Clyra Medical Technologies, Inc., a California corporation (“Borrower”) promises to pay to Vernal Bay Capital Group, LLC, a California limited liability company (the “Lender”), or to order, the principal sum of One Million Dollars ($1,000,000) or the aggregate unpaid principal amount of all Advances
July 7, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numbe
July 7, 2020	EX-10.3	Amendment dated June 30, 2020 to License Agreement with Clyra Medical Technologies, Inc. EX-10.3 2 ex193293.htm EXHIBIT 10.3 Exhibit 10.3 SECOND AMENDMENT TO LICENSE AGREEMENT THIS SECOND AMENDMENT TO LICENSE AGREEMENT (“Amendment”) is made and entered into as of this June 30, 2020, by and between BIOLARGO, INC., a Delaware corporation, and its wholly owned subsidiary BioLargo Life Technologies, Inc., a California corporation (collectively, “Licensor”), and CLYRA MEDICAL TECHNOLOGIES,
July 7, 2020	EX-10.6	Revolving Line of Credit Agreement dated June 30, 2020, between Clyra Medical and Vernal Bay Exhibit 10.6 REVOLVING LINE OF CREDIT AGREEMENT This Revolving Line of Credit Agreement is made and entered into this 30th day of June, 2020 (the “Effective Date”), by and between Vernal Bay Capital Group, LLC, a California limited liability company (the “Lender”), and Clyra Medical Technologies, Inc., a California corporation (“Borrower”). In consideration of the mutual covenants and agreements c
July 7, 2020	EX-10.5	Amendment dated June 30, 2020 to Consulting Agreement dated December 30, 2015 between Clyra Medical and Beach House Consulting LLC Exhibit 10.5 SECOND AMENDMENT TO CONSULTING AGREEMENT THIS SECOND AMENDMENT TO CONSULTING AGREEMENT (“Amendment”) is made and entered into as of this June 30, 2020, by and between Beach House Consulting, LLC, a Minnesota limited liability company (“Consultant”) and Clyra Medical Technologies, Inc., a California corporation (“Client”), with respect to the following: r e c i t a l s : A. Consultant
July 7, 2020	EX-10.7	Security Agreement dated June 30, 2020, between Clyra Medical and Vernal Bay Exhibit 10.7 SECURITY AGREEMENT This SECURITY AGREEMENT is dated as of June 30, 2020, and made by and between Clyra Medical Technologies, Inc., a California corporation, with offices at 4830 West Kennedy Blvd., Ste. 600, Tampa, FL 33069 (“Debtor”), and Vernal Bay Capital Group, LLC, a California limited liability company, with offices at 1601 Dove Street, Suite 250, Newport Beach CA 92660 (“Secure
July 2, 2020	EX-24	LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS roberts poa.htm Exhibit 24 LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby constitutes and appoints John R. Browning acting singly and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: 1. execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer or director o
May 27, 2020	DEF 14A	- FORM DEF 14A DEF 14A 1 blgo20200526def14a.htm FORM DEF 14A Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi
May 19, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-19709 BI
May 18, 2020	NT 10-Q/A	- FORM NT 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25/A NOTIFICATION OF LATE FILING Amendment No. 1 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition
May 15, 2020	NT 10-K	- FORM NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: ===
May 7, 2020	PRER14A	- FORM PRER14A Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Amendment No. 1 PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De
April 30, 2020	424B4	PROSPECTUS 26,669,650 shares of common stock Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-233534 PROSPECTUS 26,669,650 shares of common stock This prospectus relates to the offer and sale of up to 26,669,650 shares of common stock, par value $0.00067, of BioLargo, Inc., a Delaware corporation, by the selling stockholders identified herein (referred to collectively herein as the “selling stockholders,” or individual
April 30, 2020	424B4	PROSPECTUS 13,801,119 shares of common stock Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-222572 PROSPECTUS 13,801,119 shares of common stock This prospectus relates to the offer and sale of up to 13,801,119 shares of common stock, par value $0.00067, of BioLargo, Inc., a Delaware corporation, by (i) Vista Capital Investments, LLC (“Vista Capital”), (ii) FirstFire Global Opportunities Fund, LLC (“FirstFire”), (iii)
April 30, 2020	424B4	PROSPECTUS 36,090,857 shares of common stock Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-215730 PROSPECTUS 36,090,857 shares of common stock This prospectus relates to the sale of up to 36,090,857 shares of our common stock by persons who have purchased shares in a series of private placements. The aforementioned persons are sometimes referred to in this prospectus as the selling stockholders. The shares offered u
April 28, 2020	POS AM	- FORM POS AM Table of Contents As filed with the Securities and Exchange Commission on April 27, 2020 Registration No.
April 28, 2020	POS AM	- FORM POS AM Table of Contents As filed with the Securities and Exchange Commission on April 27, 2020 Registration No.
April 28, 2020	PRE 14A	- FORM PRE 14A Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S
April 27, 2020	POS AM	- FORM POS AM Table of Contents As filed with the Securities and Exchange Commission on April 27, 2020 Registration No.
April 21, 2020	424B4	44,714,286 shares of common stock Filed pursuant to Rule 424(b)(4) Registration Number 333-237651 PROSPECTUS 44,714,286 shares of common stock This prospectus relates to the offer and sale of up to 44,714,286 shares of common stock, par value $0.
April 16, 2020	DEL AM	BLGO / BioLargo, Inc. DEL AM - - FORM DEL AM BioLargo, Inc. 14921 Chestnut St. Westminster, CA 92683 April 16, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BioLargo, Inc. Registration Statement on Form S-1 Filed April 10, 2020 File No. 333-237651 Ladies and Gentlemen: This letter follows your conversation with our outside counsel regarding the above-referenced
April 10, 2020	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California Corporation Odor-No-More, Inc., a California Corporation Clyra Medical Technologies, Inc., a California Corporation* BioLargo Water Investment Group, Inc., a California Corporation BioLargo Water, Inc., a Canadian Corporation** BioLargo Development Corp., a California Corporation BioLargo Engineering, Sc
April 10, 2020	S-1	BLGO / BioLargo, Inc. S-1 - Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on April 10, 2020 Registration No.
April 7, 2020	EX-24	LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS roberts poa.htm Exhibit 24 LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby constitutes and appoints John R. Browning acting singly and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: 1. execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer or director o
March 31, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2020 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numb
March 31, 2020	EX-10.1	Purchase Agreement, dated as of March 30, 2020 by and between BioLargo, Inc. and Lincoln Park Capital Fund, LLC. Exhibit 10.1 Execution Version PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of March 30, 2020, by and between BIOLARGO, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and
March 31, 2020	EX-4.1	Registration Rights Agreement, dated as of March 30, 2020, by and between BioLargo, Inc. and Lincoln Park Capital Fund, LLC Exhibit 4.1 Execution Version REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of March 30, 2020, by and between BIOLARGO, INC., a Delaware corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein sha
March 31, 2020	EX-99.1	BioLargo 2019 Annual Report Highlights Record Revenues, Exhibit 99.1 BioLargo 2019 Annual Report Highlights Record Revenues, New Channel Partnerships, and Commercialization Milestones Iodine Solutions in the Works to Help Combat COVID-19 Crisis Westminster, CA – March 31, 2020 – BioLargo, Inc. (OTCQB:BLGO), an innovator of technology-based products and environmental engineering solutions provider, filed with the SEC its 2019 Annual Report on Form 10-K
March 31, 2020	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant BioLargo Life Technologies, Inc., a California Corporation Odor-No-More, Inc., a California Corporation Clyra Medical Technologies, Inc., a California Corporation* BioLargo Water Investment Group, Inc., a California Corporation BioLargo Water, Inc., a Canadian Corporation** BioLargo Development Corp., a California Corporation BioLargo Engineering, Sc
March 31, 2020	10-K	BLGO / BioLargo, Inc. 10-K - Annual Report - FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-19
March 31, 2020	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numb
March 30, 2020	NT 10-K	BLGO / BioLargo, Inc. NT 10-K - - FORM NT 10-K NT 10-K 1 blgo20200330nt10k.htm FORM NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report o
March 23, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2020 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numb
March 23, 2020	EX-99.1	Continuing Operations Exhibit 99.1 BioLargo Continuing Operations Through the COVID-19 Crisis Answering the call for hand sanitizer production Westminster, CA – March 23, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today released a statement from its President & CEO, Dennis P. Calvert about how it and its subsidiaries are handling the o
March 3, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2020 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File Numbe
March 3, 2020	EX-99.1	Slide presentation Exhibit 99.1
February 27, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2020 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File N
February 27, 2020	EX-10.3	2020 Engagement Extension Agreement with CFO Exhibit 10.3 BioLargo, Inc. 2020 Engagement Extension Agreement This Engagement Extension Agreement (the “Extension”) references the Engagement Agreement and Scope Letter dated February 1, 2008 (“2008 Agreement”) by and between CFO 911 (Charles K. Dargan II) (the “Advisor)” and BioLargo, Inc. (the “Company”), and written extensions to the Agreement (the “Prior Extensions”), pursuant to which Charl
February 12, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2020 BioLargo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19709 65-0159115 (State or other jurisdiction of incorporation) (Commission File N
February 12, 2020	EX-99.1	Expands Global Exhibit 99.1 Draft Press Release for BKT Review BioLargo Expands Global Reach, Signs Joint Venture Agreement with BKT & Tomorrow Water featuring CupriDyne Clean Based Products Westminster, CA – February 12, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company announced that it had executed a “Joint Venture Framework Agreemen

BLGO / BioLargo, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)